News

Here's what is coming soon to NeurologyLive®.

Although not associated with diagnosis, investigators did conclude that substantial/very severe impact of headache attacks and anxiety were correlated with presence of insomnia.

Despite not being significantly superior to placebo on agitation and aggression, lithium showed a greater reduction in those with high Young Mania Rating Scale scores.

The NeurologyLive® team has compiled a roundup of our discussions with leaders in the multiple sclerosis field following the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC).

Episode 16 of the AUPN Leadership Minute features Rohit Das, MD, of UT Southwestern Medical Center; and Selim R. Benbadis, MD, FAAN, FACNS, FAES, University of South Florida Morsani College of Medicine. [WATCH TIME: 4 minutes]

Both fatigue and sleep quality were identified as potential risk factors linking sleep duration and self-rated health.

Neurology News Network for the week ending November 20, 2021.

Ali Rezai, MD, executive chair at the Rockefeller Neuroscience Institute at West Virginia University, outlined early data from a clinical trial utilizing focused ultrasound to open the blood-brain barrier in patients with mild AD.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 19, 2021.

The executive chair of the Rockefeller Neuroscience Institute at West Virginia University spoke on how technology can be used to open the blood-brain barrier in patients with AD. [WATCH TIME: 7 minutes]

The magnitude of neflamapimod’s effect on several efficacy measures proved to be consistent with the mechanism of action and prior preclinical data, with p-tau181 data suggesting a stronger effect on nonmixed Lewy body pathology.

The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on whether a newly discovered biomarker can play a role in the creation of modalities to detect SUDEP risk. [WATCH TIME: 3 minutes]

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Karl Doghramji, MD, FAASM, DFAPA.

Chaired by Jennifer Graves, MD, PhD, MAS, the presentations also feature UC San Diego Health experts Jenelle Raynowska, MD; Jennifer Yang, MD; and Anastasie Dunn-Pirio, MD. [WATCH TIME: 1 hour, 23 minutes]

Ilya Kister, MD, professor of neurology, NYU Grossman School of Medicine, discussed his surprising results from ECTRIMS, which found no evidence of wearing off with ocrelizumab (Ocrevus; Genentech).

Contrary to previous expectations, 30 minutes of social media before bedtime did not significantly increase arousal or disturb sleep for study participants.

The guideline updates previous recommendations for dopaminergic medications published in 2002, integrating new medications and formulations.

Patients with REM sleep percentage less than 15% were associated with poorer horizontal optokinetic nystagmus grades and more severe illness.

The postdoctoral scholar at the University of Iowa commented on why the multiple sclerosis field should lean on registered dietitians to help alleviate symptoms of patients with multiple sclerosis. [WATCH TIME: 2 minutes]

The findings, which suggest that high plasma GFAP levels are parallel with AD and are markers of tau pathology, hold important implications in facilitating the detection of Alzheimer disease, particularly in the preclinical stage.

Ali Rezai, MD, executive chair of the Rockefeller Neuroscience Institute at West Virginia University, provided an overview of FUS technology and its use in opening the blood-brain barrier.

A higher incidence of gastrointestinal events was observed in the treatment group compared with placebo, similar to what was seen in clinical trials of AMX0035 in amyotrophic lateral sclerosis.

Discussing cognitive behavioral therapy for patients with MS, the associate professor of Physical Medicine and Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine mentioned different therapeutic options that can benefit this patient population. [WATCH TIME: 3 minutes]

In addition to changes in CCL2 levels, anxiety and health-related quality of life were both significantly increased in both the valproate and add-on levetiracetam groups.

The postdoctoral scholar at the University of Iowa discussed the importance of understanding more about the effects of diet and how it is managed when caring for a patient with multiple sclerosis. [WATCH TIME 3 minutes]

The director of the Comprehensive Epilepsy Center at NYU Langone discussed his recently published research, which identified a novel biomarker for sudden unexpected death in epilepsy.

Anna Kratz, PhD, associate professor of Physical Medicine & Rehabilitation, University of Michigan Medicine, spoke to the benefits of a multifaceted approach to managing fatigue for patients with multiple sclerosis.

Results outline secondary end points, which follow previously reported data on the AMBAR study’s primary end points, including delay in cognitive and functional decline in patients with AD.

The associate professor of Physical Medicine & Rehabilitation and research nonclinical psychologist at the University of Michigan Medicine discussed challenges when addressing fatigue, as well as the need to integrate digital tools for patients with MS. [WATCH TIME: 4 minutes]

The long-term benefits observed were due to maintenance of the early effect, rather than any additional benefit accrued after 90 days of the initial event, with no evidence either of rebound or loss of benefit.